DOLEŽELOVÁ, Hana, Pavel ŠLAMPA, Barbora ONDROVÁ, Jana GOMBOŠOVÁ, Štěpánka SOVADINOVÁ, Tomáš NOVOTNÝ, Karol BOLČÁK, Jana RŮŽIČKOVÁ, Ludmila HYNKOVÁ and Marie FORBELSKÁ. The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study. Neoplasma. Slovakia: Slovak Academic Press Ltd., 2008, vol. 55, No 5, p. 437-441. ISSN 0028-2685.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study
Name in Czech The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study
Authors DOLEŽELOVÁ, Hana (203 Czech Republic, guarantor), Pavel ŠLAMPA (203 Czech Republic), Barbora ONDROVÁ (203 Czech Republic), Jana GOMBOŠOVÁ (203 Czech Republic), Štěpánka SOVADINOVÁ (203 Czech Republic), Tomáš NOVOTNÝ (203 Czech Republic), Karol BOLČÁK (203 Czech Republic), Jana RŮŽIČKOVÁ (203 Czech Republic), Ludmila HYNKOVÁ (203 Czech Republic) and Marie FORBELSKÁ (203 Czech Republic).
Edition Neoplasma, Slovakia, Slovak Academic Press Ltd. 2008, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.179
RIV identification code RIV/00216224:14110/08:00034039
Organization unit Faculty of Medicine
UT WoS 000259468300011
Keywords in English positron emission tomography;18-F-fluorodeoxyglucose;radiotherapy;cervical carcinoma
Tags 18-F-fluorodeoxyglucose, cervical carcinoma, positron emission tomography, radiotherapy
Tags International impact, Reviewed
Changed by Changed by: RNDr. Marie Forbelská, Ph.D., učo 2120. Changed: 29/6/2009 08:54.
Abstract
Positron emission tomography (PET) is used to distinguish between benign and malign tumors, to diagnose relapse or post-therapeutic changes. Lately, PET is used to predict the treatment response. and also a complementary method to determine target volumes in radiotherapy. Daily using of PET in the oncology praxis can change treatment strategy and improve its outcome. Results of this pilot study show the role of PET with 8-F-fluorodeoxyglucose (18FDG) for staging of cervical carcinoma and in the radiotherapeutic planning. Between March 2005 and May 2007, 51 patients with cervical carcinoma were treated with combination of external beam radiotherapy and HDR brachytherapy, with or without concomitant cisplatin. The lymphatic nodes treatment field size was determined by PET/CT fusion. Treatment results were evaluated by PET 3 and 9 months after treatment. The differences in the results of PET and CT were evaluated in this study. In 32 cases (62.75%) the results of PET and CT were identical, in 14 cases (27.45%) the nodal involvement was more extensive according to PET, in 5 cases (9.8%) the nodal involvement was more extensive according to CT. PET results 3 months after treatment were as follows: in 3 cases (5.88%) stable disease, in 35 cases (68.63 %) negative, in 4 cases (7.84%), progression of disease, in 3 cases (5.88 %) partial regression. There were no false positive results caused by inflammatory reaction persisting 3 months after radiotherapy, as was confirmed by repeating PET 9 months after treatment. The results of this study confirmed the important role of PET in diagnosis and treatment of cervical carcinoma and in determination of target volumes in radiotherapy. PET was found to be a standard staging examination of cervical carcinoma in Masaryk Memorial Cancer Institute. The predictive value of PET has not yet been validated. Key words: positron emission tomography, 18-F-fluorodeoxyglucose, radiotherapy, cervical carcinoma
Abstract (in Czech)
Positron emission tomography (PET) is used to distinguish between benign and malign tumors, to diagnose relapse or post-therapeutic changes. Lately, PET is used to predict the treatment response. and also a complementary method to determine target volumes in radiotherapy. Daily using of PET in the oncology praxis can change treatment strategy and improve its outcome. Results of this pilot study show the role of PET with 8-F-fluorodeoxyglucose (18FDG) for staging of cervical carcinoma and in the radiotherapeutic planning. Between March 2005 and May 2007, 51 patients with cervical carcinoma were treated with combination of external beam radiotherapy and HDR brachytherapy, with or without concomitant cisplatin. The lymphatic nodes treatment field size was determined by PET/CT fusion. Treatment results were evaluated by PET 3 and 9 months after treatment. The differences in the results of PET and CT were evaluated in this study. In 32 cases (62.75%) the results of PET and CT were identical, in 14 cases (27.45%) the nodal involvement was more extensive according to PET, in 5 cases (9.8%) the nodal involvement was more extensive according to CT. PET results 3 months after treatment were as follows: in 3 cases (5.88%) stable disease, in 35 cases (68.63 %) negative, in 4 cases (7.84%), progression of disease, in 3 cases (5.88 %) partial regression. There were no false positive results caused by inflammatory reaction persisting 3 months after radiotherapy, as was confirmed by repeating PET 9 months after treatment. The results of this study confirmed the important role of PET in diagnosis and treatment of cervical carcinoma and in determination of target volumes in radiotherapy. PET was found to be a standard staging examination of cervical carcinoma in Masaryk Memorial Cancer Institute. The predictive value of PET has not yet been validated. Key words: positron emission tomography, 18-F-fluorodeoxyglucose, radiotherapy, cervical carcinoma
PrintDisplayed: 27/5/2024 01:50